How Did US Ecology Inc(NASDAQ:ECOL) and Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP) Fare During The Third Quarter?


Atlanta, GA – Scibility Media – 11/11/2014.

This article discusses two companies: US Ecology Inc(NASDAQ:ECOL) and Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)

US Ecology Inc(NASDAQ:ECOL) reported its third quarter financial results after the markets closed on Nov. 5th, 2014. The Idaho-based company announced that it had recorded a net income of $13.3 million, or $0.61 per diluted share, for the period. This figure marks a substantial increase from US Ecology’s $10.3 million, or $0.56 per diluted share, figure recorded during the same period of the previous fiscal year.

The waste management company provides a variety of services through its subsidiaries, including waste treatment, disposal, recycling, and transportation to both commercial and government entities. US Ecology’s clients include oil refineries, chemical production facilities, electric utilities, biotechnology companies, and academic institutions.

Starved For Yield? Find New Investment Opportunities.

Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP) alsoreported its third quarter financial results on Nov. 10th, 2014. The financial figures included a net loss of $7.4 million, or $0.71 per share. While the net loss total may be greater than its third quarter 2013 figure of $3.1 million, Toni’s per share loss actually decreased from the $0.87 mark recorded during the same period of the previous fiscal year. Additionally, Tonix’s cash total has increased from $8.2 million on Dec. 31st, 2013 to $46.2 million.

The New York-based company identifies and develops pharmaceutical products that are used to treat disorders of the central nervous system. Tonix’s products include TNX-102, which would be used to treat fibromyalgia and post-traumatic stress disorder.

Are You Looking For An Edge? Equipress Is A Nonbiased Platform That Connects Investors With Public Companies. Get An Edge Today!

About is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.

Sign-up for free now to experience the full benefits of EquiPress pre-launch.

Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.

Can’t find your company on EquiPress? Send us an email to and we will contact them for you.

Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.

Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit for complete risks and disclosures.


Leave A Reply